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OBJECTIVE: Fetuin-A is a protein secreted from the liver that inhibits arterial calcification deposition and can
contribute to insulin resistance. Hyperthyroidism is also associated with insulin resistance. It is not known
whether hyperthyroidism has an effect on fetuin-A levels.
METHODS: We measured fetuin-A levels and homeostasis model of assessment-insulin resistance before
hyperthyroidism treatment was initiated and after euthyroidism was achieved. A total of 42 patients diagnosed
with hyperthyroidism were enrolled in this study. Fetuin-A, insulin, high-sensitivity C-reactive protein, fasting
blood glucose, free T3 (fT3), free T4 (fT4), and thyrotropin were measured before and after euthyroidism was
established.
RESULTS: Basal fasting blood glucose, high-sensitivity C-reactive protein, insulin, c-peptide, homeostasis model
of assessment-insulin resistance, fT3, fT4 and fetuin-A levels were significantly decreased after euthyroidism
was achieved (Table 1). Basal fasting blood glucose (r:0.407, p:0.008), high-sensitivity C-reactive protein (r:0.523,
p,0.0001), insulin (r:0.479, p:0.001), homeostasis model of assessment-insulin resistance (r:0.541, p,0.0001), fT3
(r:0.492, p:0.001) and fT4 (r:0.473, p:0.002) were positively correlated with basal fetuin-A levels. Basal
thyrotropin levels were significantly negatively correlated (r:-0.553, p,0.0001) with basal fetuin-A levels.
CONCLUSION: Our findings suggest that hyperthyroidism influences fetuin-A levels.
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& INTRODUCTION
Fetuin-A is a protein secreted from the liver that inhibits
arterial calcium deposition (1). It interacts with calcium and
phosphorus in the serum, increasing their solubility and
inhibiting calcium crystal precipitation. Fetuin-A-knockout
mice have been shown to develop greater soft tissue
calcification compared with wild-type control mice (2-3).
Lower fetuin-A levels are associated with cardiovascular
disease (CVD) events and all-cause mortality in end-stage
renal disease (ESRD) (4).
Fetuin-A inhibits insulin receptor tyrosine kinase activity
in the muscle and liver, thereby inhibiting insulin signaling
and introducing insulin resistance in vitro (5). In humans,
fetuin-A may be an important link between obesity and
insulin resistance (6-7). Fetuin-A concentrations are also
associated with hepatosteatosis and are elevated in patients
with insulin resistance (8). Fetuin-A can also be valuable for
the prediction of new-onset type 2 diabetes. In the European
Prospective Investigation into Cancer and Nutrition Study,
circulating fetuin-A levels predicted the incidence of type 2
diabetes during a 7-yr follow-up (9). In the Health, Aging,
and Body Composition study, serum fetuin-A levels were
also significantly associated with incident diabetes during a
6-yr follow-up (10).
Hyperthyroidism is also associated with insulin resistance
and elevated blood glucose levels (11-12). However, the link
between hyperthyroidism and insulin resistance has not been
fully elucidated. To our knowledge, fetuin-A levels have not
been measured in hyperthyroidism. In this study, we aimed
to investigate the level of fetuin-A in hyperthyroidism.
& METHODS
A total of 42 patients diagnosed with hyperthyroidism
were enrolled in this study. Blood samples were collected
before hyperthyroidism treatment was initiated and after
euthyroidism was achieved. Serum glucose levels were
measured with an autoanalyzer with the manufacturer’s
commercially available kits (Cobas 8000, Roche Diagnostics,
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Mannheim, Germany). Free T3, free T4, TSH and insulin
levels were measured with a chemiluminescence immuno-
metric assay using a UniCell DXI 800 analyzer (Beckman
Coulter Inc., Fullerton, CA, USA). Serum hsCRP levels were
determined using an ELISA according to the manufacturer’s
instructions (DRG International, Inc., USA). The intra- and
inter-assay coefficients of variation were below 10%. Serum
fetuin-A levels were measured with a human fetuin-A
ELISA kit (BioVendor Laboratory Medicine, Brno, Czech
Republic). The analytical sensitivity of the human fetuin-A
ELISA kit was 0.35 ng/mL. The intra- and inter-assay
coefficients of variation were below 6.5%. The exclusion
criteria were previously known diabetes mellitus, athero-
sclerotic vascular disease, infections, malignancy, amyloi-
dosis, autoimmune diseases, alcohol consumption or
smoking history, congestive heart failure, and liver or renal
dysfunction. HOMA-IR was calculated using the following
formula:
HOMA-IR= fasting glucose (mmol/L)6fasting insulin
(mU/mL)/22.5.
The distribution of continuous variables was determined
by the Kolmogorov-Smirnov test. A paired-sample t test
was performed to analyze initial and final values with a
normal distribution. A Wilcoxon signed rank test was used
to analyze data with a skewed distribution. Pearson’s and
Spearman’s analyses were used to identify correlations
between study parameters. For all statistics, a two-sided p-
value ,0.05 was considered statistically significant. All
analyses were performed with SPSS 15.0 for Windows.
& RESULTS
Of the 42 hyperthyroid patients (48.5¡15.0 years old), 27
patients were female, and 15 were male. Among the causes
of hyperthyroidism, 30 patients had Graves’ disease, 11
patients had toxic adenoma, and 1 patient had two toxic
nodules. Euthyroidism was achieved in 3.0¡0.7
(mean¡SD) months. Basal fasting blood glucose, hsCRP,
insulin, HOMA-IR, fT3, fT4, calcium and fetuin-A levels
were significantly decreased after euthyroidism was
achieved (Table 1) (Figure 1). Basal fasting blood glucose
(r:0.407, p:0.008), hsCRP (r:0.523, p,0.0001), insulin (r:0.479,
p:0.001), HOMA-IR (r:0.541, p,0.0001), fT3 (r:0.492, p:0.001)
and fT4 (r:0.473, p:0.002) were positively correlated with
basal fetuin-A levels (Figures 2, 3). Basal TSH levels were
significantly negatively correlated (r:-0.553, p,0.0001) with
basal fetuin-A levels. The basal body mass index (before:
Table 1 - Biochemical results before and after euthyroidism was achieved (mean¡SD).
Parameter (reference values) Hyperthyroid Euthyroid p-value
Fetuin-A (ng/mL) 468.7¡143.5 234.5¡103.8 ,0.0001
FT3 (pg/mL) (2.5-3.9) 8.6¡2.3 2.7¡0.3 ,0.0001
FT4 (ng/dL) (0.61-1.06) 4.7¡1.6 1.2¡0.4 ,0.0001
TSH (mIU/mL) (0.41-4.25) 0.006¡0.014 0.986¡0.467 ,0.0001
Fasting blood glucose (mg/dL) (70-
110)
113.1¡15.6 94.8¡22.2 ,0.0001
Insulin (mU/mL) (1.9-23) 13.1¡2.5 8.5¡2.1 ,0.0001
HOMA-IR 3.69¡1.07 2.00¡0.67 ,0.0001
hsCRP (mg/L) (0.068-8.2) 6.27¡2.65 1.92¡0.79 ,0.0001
Calcium (mg/dL) (8.6-10.2) 10.1¡0.4 9.4¡0.3 ,0.0001
Figure 1 - The comparison of fetuin-A (ng/mL) levels during hyperthyroidism and euthyroidism.
Hyperthyroidism and fetuin-A
Pamuk BO et al.
CLINICS 2013;68(3):379-383
380
Figure 2 - The correlation between free FT4 (reference range: 0.61-1.06 ng/dL) and fetuin-A (ng/mL) levels.
Figure 3 - The correlation between TSH (uIU/mL) and fetuin-A (ng/mL) levels.
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27.1¡3.2, after: 28.2¡3.7, p,0.0001) increased significantly
after euthyroidism was achieved.
& DISCUSSION
In this study, we found that fetuin-A levels decreased
significantly with hyperthyroidism treatment. To our
knowledge, this is the first study investigating the effect of
hyperthyroidism on fetuin-A levels. In this study, hsCRP
levels also decreased significantly with the normalization of
thyroid hormones. Furthermore, fetuin-A levels were
positively correlated with thyroid hormone, HOMA-IR
and hsCRP levels.
Fetuin-A is a liver-derived blood protein that acts as a
potent inhibitor of ectopic mineralization. Monomeric
fetuin-A protein binds to small clusters of calcium and
phosphate. Therefore, fetuin-A is a mineral carrier protein
and a systemic inhibitor of pathological mineralization that
complements local inhibitors that act in a cell-restricted or
tissue-restricted fashion (13). Fetuin-A deficiency is asso-
ciated with soft tissue calcification in mice and humans.
Fetuin-A is a prominent serum glycoprotein as well as a
major noncollagenous component of mineralized bone in
mammals. In vitro, fetuin-A can inhibit or stimulate
osteogenesis, depending on its concentrations (17). Rasul
et al. previously found a positive correlation between fetuin-
A and bone alkaline phosphatase in type 2 diabetic males. In
females, fetuin-A was significantly negatively associated
with C-telopeptide levels (18). However, the researchers did
not measure thyroid hormones in that study. Thyroid
hormones increase bone turnover markers, and hyperthyr-
oidism increases bone turnover. Fetuin-A may be increased
in hyperthyroidism through a mechanism related to bone
metabolism. Fetuin-A has been studied in several metabolic
derangements; however, its role has not been studied in
hyperthyroidism. Therefore, we could not compare our
results with previous studies.
Sato et al. examined the effects of T3 on the expression of
calcification-associated genes and found that a physiological
concentration of T3 increased the mRNA level of matrix G1a
protein (MGP), which is a potent inhibitor of vascular
calcification in vivo (19). They also showed that hyperthyr-
oidism upregulated MGP mRNA 4.5 fold and reduced the
calcium content of rat aortic smooth tissue by 11%. Fetuin-A
also inhibits tissue calcification in a similar fashion; there-
fore, we hypothesize that there may be an interaction
between fetuin-A synthesis and thyroid hormones because
we found a positive correlation between these two
parameters. To our knowledge, no experimental study in
the literature has investigated the effect of thyroid hormones
on the mRNA levels of fetuin-A. Hypercalcemia is a well-
known complication of hyperthyroidism, and stimulating
fetuin-A synthesis may be an adaptation to prevent ectopic
tissue calcification in hyperthyroidism. In a previous study
of 32 thyrotoxic teenage girls, 21 (66%) showed some degree
of calcification compared with 73 of 600 (12%) in the control
group (22). Yamashita et al. previously observed that
fibroblast growth factor (FGF)-23 levels (which are also
related to soft tissue calcification) decreased significantly
with hyperthyroidism treatment (23). However, they did
not measure fetuin-A levels, and we therefore cannot
compare our results with that study.
Fetuin-A levels have been found to be higher in diabetes
and inflammatory diseases, such as ankylosing spondylitis
(13). In addition to its functions as an inhibitor of tissue
calcification, fetuin-A is an endogenous inhibitor of the
insulin receptor tyrosine kinase (14), and fetuin-A-knockout
mice exhibit increased insulin sensitivity (15). Recent
studies have associated high levels of fetuin-A with an
increased risk of type 2 diabetes incidence (16), insulin
resistance, hepatosteatosis (8) and metabolic syndrome (7).
Li et al. previously showed that fetuin-A plays a protective
role in systemic inflammation by activating high-mobility
group box 1 (HMGB1) synthesis (20). Hyperthyroidism may
also initiate an inflammatory cascade and eventually
stimulate fetuin-A synthesis. Insulin resistance in
hyperthyroidism may also be related to the increased levels
of fetuin-A. Yavuz et al. previously showed that levothyr-
oxine treatment of goiter patients significantly increased
hsCRP at 16 weeks (21). In accordance with that study,
we found a significant decrease in hsCRP levels with
hyperthyroidism treatment. Fetuin-A also has strong anti-
inflammatory properties (13). In our study, fetuin-A levels
decreased with hsCRP levels, which may also be related to
the inflammation-fetuin-A interaction. In our study, insulin
levels were significantly positively correlated with fetuin-A
levels; furthermore, insulin levels and fetuin-A levels were
decreased after euthyroidism was achieved. The relation-
ship between fetuin-A and insulin has been studied in both
clinical and experimental studies. Fetuin-A binds to insulin
receptors in adipose and muscular tissue and inhibits
insulin receptor tyrosine kinase activity as well as insulin
receptor autophosphorylation in vivo and in vitro (13).
Fetuin-A has also been suggested to potentially cause
insulin resistance and metabolic syndrome (13).
In the present study, fasting glucose levels decreased
significantly with hyperthyroidism treatment. Fasting glu-
cose levels were significantly positively correlated with
fetuin-A levels. It was previously shown that higher fetuin-
A concentrations were associated with type 2 diabetes and
insulin resistance (24). In another study, fetuin-A levels
were significantly correlated with fasting plasma glucose
and CRP (25). The present study is in accordance with these
findings, as fetuin-A levels decreased significantly as the
fasting glucose levels and insulin resistance decreased after
hyperthyroidism treatment. Atherosclerosis has been shown
to be enhanced in hypothyroidism (26). The anti-atherogenic
effects of thyroid hormones may also be related to fetuin-A.
Further clinical and experimental studies investigating the
effect of hypothyroidism on fetuin-A levels may reveal its
influence on atherosclerosis in hypothyroidism.
In conclusion, this study showed that fetuin-A levels
declined significantly after hyperthyroidism treatment.
Fetuin-A levels were also correlated with thyroid hormones
and insulin resistance. Further experimental studies are
needed to elucidate the molecular link between the
hormones regulating tissue calcification and thyroid hor-
mones.
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